Comments on: Dendreon Saga Heads Toward Climax, As Cancer Drug Aims to Prove It Prolongs Lives

By: Dendreon’s Provenge and other hot drugs in Prostate Cancer | Pharma Strategy Blog

Tue, 26 Oct 2010 21:23:50 +0000

[...] Dendreon Saga Heads Toward Climax, As Cancer Drug Aims to Prove It Prolongs Lives (xconomy.com) [...]

By: The Medical Quack: Provenge – the Verdict is Near for Dendreon’s Prostate Cancer Drug

Tue, 14 Apr 2009 23:09:43 +0000

[...] followed to 2 of the individuals on the advisory committee. If you missed the fireworks, this page gives a good summary of events. The money side with investors truly contributed to the drama substantially as well [...]

By: Dendreon: Will they say or Will they go? | nPostBio Blog

Dendreon: Will they say or Will they go? | nPostBio Blog — Tue, 14 Apr 2009 16:47:42 +0000

[...] this morning that Provenge ride will continue on a very high note. The clinical data on their 512 patient impact study mandated by the FDA after they denied approval back in May of 2007 shows positive and statistically [...]

By: p3analyze

p3analyze — Thu, 09 Apr 2009 22:53:08 +0000

nice summary but for a necessary correction:

The interim analysis penalized hurdle of success for the upcoming final anlaysis of the ongoing IMPACT trial is a 22% improvement in median survival.

By: bob denver

bob denver — Thu, 09 Apr 2009 19:09:36 +0000

By: Bob

Bob — Tue, 07 Apr 2009 19:43:56 +0000

Interesting article in the WSJ:
http://online.wsj.com/article/SB123906164489395123.html

By: mason

mason — Mon, 06 Apr 2009 06:26:17 +0000

will DNDN succeed in spite of itself? lol history tells me to bet against it. The company has issues, even if the science does not. Everything since they FDA shot them down has been last bid attempts to salvage stock market value, asking for another recount, if you will. They are snake oil IMHO.

By: Bob

Bob — Sat, 04 Apr 2009 16:48:46 +0000

Another company betting the Easter egg basket on Prostate Cancer…

I know the Federal Govt. is looking at these expensive treatments, that, at best increase life-span by a few months…

By: Paul Sanders

Paul Sanders — Sat, 04 Apr 2009 16:23:09 +0000

What will be the extended life expectancy as a result of using Provenge and what will be its costs?

By: Mike Scott

Mike Scott — Sat, 04 Apr 2009 10:32:53 +0000

With the deepest respect to Eric Newland …

(a) Dr. Hussain is a “she”, not a “he” and she has been involved in clinical research on nearly every significant prostate cancer drug that is or has recently been in development. That’s her job. She’s a specialized clinical researcher in prostate cancer! That’s not a conflict of interest. That IS her interest, and I have profound respect for her integrity.

(b) More than half the panel at the CBER hearings had conflicts of interest because their future research funding was tied to the development of immunotherapeutics for treatment of cancer (but no one seems to recognize that that might bias their opinions). Mr Timmerman has pointed out in his article that one member of the panel did effectively admit that after the meeting.

By: Dendreon Causing Stir Again | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Humor and Updates on the Latest Events in the Biotechnology and Pharmaceutical Industries

Fri, 03 Apr 2009 22:02:27 +0000

[...] Dendreon has a very long and dramatic history. Luke Timmerman at Xconomy did an amazing piece today on the company’s long journey which we highly recommend you read – especially if you’re a bit late to the ballgame. Take a look here. [...]

By: The full Provenge saga « THE “NEW” PROSTATE CANCER INFOLINK

The full Provenge saga « THE “NEW” PROSTATE CANCER INFOLINK — Fri, 03 Apr 2009 20:28:00 +0000

[...] Phase III (IMPACT) trial of Provenge (expected some time this month), you read the well-constructed history of the clinical development of Provenge that has been posted to the Xconomy.com web site [...]

By: Speaking of DNDN . . .

Speaking of DNDN . . . — Fri, 03 Apr 2009 18:02:41 +0000

[...] case you’re new to the table, here’s an excellent backgrounder on DNDN. And if you’re using a Google Alert on [...]

By: eric newland

eric newland — Fri, 03 Apr 2009 17:48:24 +0000

Hussain – if I remember – had a conflict of interest as he was involved in support of a competing prostate drug – and his vote was detrimental in the approval process.

By: David Miller

David Miller — Fri, 03 Apr 2009 13:51:50 +0000

This will be one of the more interesting days in biotech in 2009. I expect the conference room in Chicago where the data are to be presented to be absolutely packed.

David Miller

By: IRIS International Celebrates 30 Years of Excellence as Leading In - MSN MoneyCentral | Search Way

Fri, 03 Apr 2009 12:38:41 +0000

[...] Dendreon Saga Heads Toward Climax, As Cancer Drug Aims to Prove It – XconomyDendreon has all the ingredients of a Hollywood thriller: Life and death on the line. Millions of dollars at stake. Fast money in the stock market. Cutting-edge technology that aspires to achieve the impossible. The Seattle biotech company (NASDAQ [...]